Literature DB >> 3526984

The safety and efficacy of esmolol during myocardial revascularization.

D Girard, B J Shulman, D M Thys, B P Mindich, S K Mikula, J A Kaplan.   

Abstract

The safety and efficacy of esmolol during high-dose fentanyl anesthesia were studied in 37 patients undergoing coronary artery bypass grafting (CABG). The anesthetic management consisted of fentanyl 75 micrograms/kg, pancuronium 0.15 mg/kg, and O2. To assess the safety of esmolol, it was administered in a double-blind manner to 17 anesthetized patients prior to surgical incision. Infusion of the drug was increased in stepwise fashion to obtain administration rates between 100 and 300 micrograms X kg-1 X min-1. Esmolol produced small but significant increases in pulmonary capillary wedge pressure (PCWP) (8.3 +/- 1.7 to 13.2 +/- 2.0 mmHg) when compared with placebo (10.9 +/- 1.0 to 12.1 +/- 0.6 mmHg) (P less than 0.05). For the other studied parameters (heart rate, mean arterial pressure, central venous pressure, cardiac index, stroke index, left ventricular stroke work index, systemic vascular resistance, and peripheral vascular resistance), no significant differences were observed between esmolol and placebo. To evaluate the efficacy of esmolol, 20 patients were randomly assigned to an esmolol group (n = 11) or a placebo group (n = 9). The study medication was infused from 5 min before induction through initiation of cardiopulmonary bypass. Infusion of esmolol at 200 micrograms X kg-1 X min-1 prevented tachycardia in response to intubation. In the esmolol group the heart rate increased from 63.4 +/- 2.7 to 67.6 +/- 2.9 beats/min after intubation, while in the placebo group it increased from 61.4 +/- 4.3 to 72.4 +/- 3.4 beats/min (P less than 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3526984     DOI: 10.1097/00000542-198608000-00005

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  7 in total

1.  Esmolol--just another beta blocker?

Authors:  R I Hall
Journal:  Can J Anaesth       Date:  1992-10       Impact factor: 5.063

2.  Bolus administration of esmolol for the treatment of intraoperative myocardial ischaemia.

Authors:  D R Miller; R J Martineau
Journal:  Can J Anaesth       Date:  1989-09       Impact factor: 5.063

3.  Bolus administration of esmolol for controlling the haemodynamic response to tracheal intubation: the Canadian Multicentre Trial.

Authors:  D R Miller; R J Martineau; J E Wynands; J Hill
Journal:  Can J Anaesth       Date:  1991-10       Impact factor: 5.063

4.  Nitrous oxide does not exacerbate pulmonary hypertension or ventricular dysfunction in patients with mitral valvular disease.

Authors:  S N Konstadt; D L Reich; D M Thys
Journal:  Can J Anaesth       Date:  1990-09       Impact factor: 5.063

Review 5.  Esmolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  P Benfield; E M Sorkin
Journal:  Drugs       Date:  1987-04       Impact factor: 9.546

6.  Perioperative beta-blockers for preventing surgery-related mortality and morbidity in adults undergoing cardiac surgery.

Authors:  Hermann Blessberger; Sharon R Lewis; Michael W Pritchard; Lizzy J Fawcett; Hans Domanovits; Oliver Schlager; Brigitte Wildner; Juergen Kammler; Clemens Steinwender
Journal:  Cochrane Database Syst Rev       Date:  2019-09-23

Review 7.  Perioperative hypertension management.

Authors:  Joseph Varon; Paul E Marik
Journal:  Vasc Health Risk Manag       Date:  2008
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.